Open AccessGene Expression of Matrix Metalloproteinases and their Inhibitors (TIMPs) in Meningiomas of Dogs
Author(s) -
Mandara M.T.,
Reginato A.,
Foiani G.,
De Luca S.,
Guelfi G.
Publication year - 2017
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.14809
Subject(s) - matrix metalloproteinase , meningioma , medicine , pathology , metastasis , real time polymerase chain reaction , cancer research , gene , cancer , biology , genetics
Background Matrix metalloproteinases ( MMP s) and tissue inhibitors of metalloproteinases ( TIMP s) are considered to be key mediators of tumor invasion and metastasis. MMP ‐2 and MMP ‐9 are expressed in meningiomas of dogs, but TIMP expression, and variations of specific MMP / TIMP ratios still are unknown in this tumor. Hypothesis/Objectives Expression of MMP / TIMP might increase progressively from grade I to grade III meningioma. Therefore, genetic expression of MMP ‐2 and MMP ‐9, and specific TIMP ‐2 and TIMP ‐1, respectively, has been investigated in meningiomas of different grades. Animals Selected formalin‐fixed paraffin‐embedded tissue from 43 meningiomas of dogs was evaluated. Methods Genetic material was obtained from pathologic samples and used for quantitative reverse transcriptase real‐time polymerase chain reaction ( RT ‐ qPCR ). Results MMP ‐9 was not expressed in all of the tumors, but MMP ‐2 was significantly more expressed in papillary meningioma. Likewise, the MMP ‐2/ TIMP ‐2 ratio was numerically higher in papillary meningiomas compared to all grades (>3.5 times) showing a strong bias in favor of metalloproteinase. In the papillary meningioma, TIMP ‐1 gene expression was significantly higher than in grades I and III . Conclusions and Clinical Importance MMP ‐2/ TIMP ‐2 imbalance might contribute to the aggressive biologic behavior of papillary meningiomas in dogs. TIMP ‐1 expression may play a role independent of MMP ‐9 expression in neoplastic progression. These results further support that therapeutic and prognostic evaluations of dogs with meningioma need to be addressed according to different histologic patterns as is performed in humans.